Swiss National Bank Purchases 15,100 Shares of Covetrus, Inc. (NASDAQ:CVET)

Swiss National Bank grew its position in Covetrus, Inc. (NASDAQ:CVETGet Rating) by 6.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 259,540 shares of the company’s stock after acquiring an additional 15,100 shares during the period. Swiss National Bank owned 0.19% of Covetrus worth $5,385,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of CVET. Select Equity Group L.P. raised its stake in shares of Covetrus by 3,737.6% in the first quarter. Select Equity Group L.P. now owns 1,513,820 shares of the company’s stock valued at $25,417,000 after acquiring an additional 1,474,373 shares during the last quarter. Alpine Associates Management Inc. bought a new position in Covetrus in the 2nd quarter worth approximately $26,210,000. Dimensional Fund Advisors LP raised its position in Covetrus by 36.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,501,140 shares of the company’s stock worth $41,997,000 after purchasing an additional 661,866 shares during the last quarter. Candriam S.C.A. bought a new position in Covetrus in the 2nd quarter worth approximately $12,930,000. Finally, Wellington Management Group LLP raised its position in Covetrus by 6.2% in the 1st quarter. Wellington Management Group LLP now owns 8,357,496 shares of the company’s stock worth $140,323,000 after purchasing an additional 485,051 shares during the last quarter. Institutional investors own 92.20% of the company’s stock.

Covetrus Price Performance

CVET opened at $20.99 on Friday. The company has a fifty day moving average price of $20.95 and a two-hundred day moving average price of $20.50. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.08 and a current ratio of 1.88. Covetrus, Inc. has a 52 week low of $13.39 and a 52 week high of $21.20. The firm has a market capitalization of $2.94 billion, a PE ratio of -209.90 and a beta of 1.51.

Analyst Upgrades and Downgrades

Separately, TheStreet upgraded shares of Covetrus from a “d+” rating to a “c-” rating in a research report on Wednesday, September 28th. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $20.00.

Covetrus Profile

(Get Rating)

Covetrus, Inc, together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers.

Further Reading

Institutional Ownership by Quarter for Covetrus (NASDAQ:CVET)

Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with MarketBeat.com's FREE daily email newsletter.